On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma.

FDA grants accelerated approval to Zenocutuzumab-zbco - The Babak Lab / Bizengri, cancer, eNRGy study, FDA, non small cell lung cancer, NSCLC, OncoDaily,

Bizengri (zenocutuzumab-zbco) was approved as the first treatment for advanced pancreatic cancer and NSCLC harboring an NRG1 gene fusion.

On December 4, 2024, the U.S. Food and Drug Administration granted accelerated approval to zenocutuzumab (Bizengri®), the first approved systemic therapy for patients with advanced, unresectable, or m...

On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a…

On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma.

On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma.

Zenocutuzumab (Bizengri) targets NRG1 fusion found in about 1% of pancreatic cancers. For Colin Kiesel, it was the right drug at the right time.

This Oncology update highlights major regulatory and clinical developments across precision oncology. Key stories include FDA acceptance of the zipalertinib NDA in EGFR exon 20 NSCLC, FDA approval of VEPPANU for ESR1-mutated breast cancer, and Priority Review for Ziihera in HER2-positive GEA. Additional updates cover Truqap in PTEN-deficient prostate cancer, NICE managed access for RYBREVANT, new European approvals for serplulimab, an FDA National Priority Voucher for BIZENGRI, and RMAT designation for RZ-001 in hepatocellular carcinoma.

On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a ...

La Fundación Ven Rose de Jayuya marcó un hito en Puerto Rico al administrar por primera vez el medicamento Bizengri para tartar el cáncer, aprobado reciente ...

Merus annonce l’autorisation par la FDA de BIZENGRI® dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules NRG1+, en fonction des données de sécurité et d’efficacité issues de l’étude eNRGy BIZENGRI® est…

FDA approved Bizengri (zenocutuzumab-zbco), a drug that treats NRG1 fusion-positive cholangiocarcinoma. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled in sponsored accounts.Login Subscribe

Zenocutuzumab (Bizengri) targets NRG1 fusion found in about 1% of pancreatic cancers. For Colin Kiesel, it was the right drug at the right time.

The U.S. Food and Drug Administration (FDA) has approved Bizengri to treat an ultra-rare, aggressive cancer that forms in the bile ducts.

Partner's Bizengri has been approved for a rare form of bile duct cancer, two days after being awarded a national priority review voucher.

Partner Therapeutics’ Bizengri is now FDA approved for treating advanced cases of cholangiocarcinoma driven by NRG1 gene fusions. Partner acquired U.S. rights to this bispecific antibody from Merus in 2024.

The U.S. Food and Drug Administration (FDA) has approved Bizengri to treat an ultra-rare, aggressive cancer that forms in the bile ducts.